Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD study of zatolmilast in healthy young and elderly subjects
NCT02840279Phase 1Completed
- Sponsor
- Tetra Therapeutics
- Start
- Jun 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing BPN14770 with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 2 weeks. Started Jun 2016; status: completed.
02
Drugs
zatolmilast
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02840279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840279.